Search

Displaying results 4881 - 4890 of 10000 in total
  1. Drug

    Flumethasone

    go.drugbank.com/drugs/DB00663
    ApprovedVet approved

    This local effect on diseased areas results in a prompt decrease in inflammation, exudation and itching. … As it is a privalate salt, its anti-inflammatory action is concentrated at the site of application.

    Mixtures: LOCORTEN ANTIBIOTICO E ANTINFIAMMATORIO, LOCORTEN ANTIBIOTICO E ANTINFIAMMATORIO
  2. Drug

    XL228

    go.drugbank.com/drugs/DB05184
    Investigational

    XL228 is a novel anticancer compound designed to inhibit the insulin-like growth factor type-1 receptor (IGF1R), Src and Abl tyrosine kinases – targets that play crucial roles in cancer cell proliferation

  3. Drug

    UC-781

    go.drugbank.com/drugs/DB05871
    Investigational

    UC-781 is a thiocarboxanilide non-nucleoside reverse transcriptase inhibitor (NNRTI). It is a topical microbicide targeted against the AIDS virus.

  4. Drug

    Maytansine

    go.drugbank.com/drugs/DB19582
    Investigational

    Maytansine is a small molecule drug. Maytansine is under investigation in clinical trial NCT04189211 (A Clinical Trial of BAT8001 on Safety, Tolerability and Pharmacokinetics for Patients). … Maytansine has a monoisotopic molecular weight of 691.29 Da.

  5. Drug

    Lancovutide

    go.drugbank.com/drugs/DB05029
    Investigational

    Lancovutide, a peptide antibiotic, is in clinical development for the treatment of cystic fibrosis. … Lantibiotics are bacteriocins that are characterized by the presence of a high proportion of unusual amino acids.

  6. Drug

    TD101

    go.drugbank.com/drugs/DB06596
    Investigational

    TD101, a small interfering RNA (siRNA) designed for the treatment of pachyonychia congenita

  7. Drug

    Chlorotoxin I-131

    go.drugbank.com/drugs/DB05462
    Investigational

    Chlorotoxin I-131 is investigated in clinical trials for treating brain cancer. … Chlorotoxin I-131 binds to and reduces the activity of a matrix metalloproteinase (MMP) that regulates functioning of the chloride channels on cell membranes.

  8. Drug

    Reglitazar

    go.drugbank.com/drugs/DB04971
    Experimental

    Reglitazar, an isoxazolidine-3,5-dione derivative, is being developed by Pfizer for the treatment of diabetes. It is the first non-thiazolidenedione to enter clinical trials.

  9. Drug

    ABX1100

    go.drugbank.com/drugs/DB17655
    Investigational

    ABX1100 is an investigational Centyrin-siRNA conjugate that targets the Gys1 gene, which encodes glycogen synthase 1 (Gys1), an enzyme that is responsible for glycogen synthesis in the muscle. … It was first developed by Aro Biotherapeutics and is being investigated for the treatment of Pompe disease.[L45978]

  10. Drug

    PI-166

    go.drugbank.com/drugs/DB05859
    Experimental

    PI-166 is a small organic compound with specific avidity to liver cancer cells.